Hikal share news, announcements and annual reports
NSE: HIKALBSE: 524735Pharmaceuticals & BiotechnologySmall Cap
Hikal Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1995 on BSE, Feb 2001 on NSE
Last close ₹211.58up ₹7.18 (3.51%)BSE ₹210.95
Share price at the NSE close on 30 Oct 2026. Previous close ₹204.40.
30 Oct: open ₹205.88, high ₹223.70, low ₹204.72
52-week range of traded prices to 30 Oct 2026
₹146.25Low, 30 Mar 2026₹261.00High, 4 Dec 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,609 Cr1,090th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.18
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.28%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −2.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹76 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 3.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.57
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 40,73,4669.3% delivered
Hikal share news and announcements
727 announcements, routine notices left out, newest first. Page 15 of 15.
Mar 2008
5 Mar · Updates
The Company has entered into a long term contract manufacturing agreement with Bayer CropScience AG Germany, one of the world's largest crop protection companies, for manufacture and supply of Active Ingredients for Crop Protection products. Buyer CropScience AG is a subsidiary of Bayer AG, Germany which is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. Hikal has set up a new state-of-the-art multi purpose plant at Taloja, Dist. Raigad, Maharastra to manufacture these products. Signing of this agreement will have substantial impact on the crop protection business of the company in coming years.
Feb 2008
11 Feb · Limited Review Report
Auditor's have conducted the limited review of the Unaudited financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
21 Jan · Dividend
Interim dividend for the year 2007-2008, on the equity shares will be paid on February 11, 2008.17 Jan · Updates
Performance highlights for the Quarter ended December 31, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Dividend
Board has declared interim dividend on Equity Share Capital @ 30% (Rs.3.00 (Rupees three only) per Equity Share) in their meeting held on January 17, 2008 for the financial year 2007-08. Further the Company has fix the Record Date for payment of Interim Dividend for the year 2007-08 as February 01, 2008.8 Jan · Board meeting
To consider and take on record the Unaudited Financial Results for the quarter ended December 31, 2007. Further, in this meeting, the Board will also consider the declaration of Interim Dividend for the year 2007-2008.7 Jan · Miscellaneous
Hikal has signed a long-term agreement with Pfizer Inc., a global leader in pharmaceuticals for manufacture and supply of Active Pharmaceutical Ingredients (API's). Hikal will be manufacturing the API's at its USFDA plant at Jigani, Bangalore.
Oct 2007
18 Oct · Board meeting
The Board of Directors in their meeting held on 18th October, 2007 have discussed and approved the following : Issue of 50 Lacs (Fifty Lacs) Convertible Cumulative Redeemable Preference Shares of Rs. 100 (Rupees One Hundred) each at par aggregating to Rs. 50 Crores (Rupees Fifty Crores) with the option to convert it into the Equity Shares of the Company on private placement basis, subject to the approval of shareholders9 Oct · Board meeting
Meeting on 18 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Sep 2007
25 Sep · Legal
September 25, 2007 that "Regarding The Hindu Business Line article entitled "Pfizer gets relief on epilepsy drug as US court reverses ruling". With reference to the above-mentioned article which has appeared today, Hikal would like to state that it is neither in the finished formulation business nor does it market finished dosage forms in the US. In addition Hikal has consulted its attorneys who have confirmed that Hikal has sound patent situation. Initial communication with our customers indicate that there would be no interruptions for the supply of Gabapentin from Hikal and that they are not affected by the recent judgment of the US courts. We except it to be business as usual for Hikal and its supply of Gabapentin".11 Sep · Meeting
Minutes of the Annual General Meeting of the Company held on August 23, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
24 Aug · Dividend
Final dividend for the year 2006-2007 on the equity shares will be paid on September 14, 2007.22 Aug · Limited Review Report
Auditors have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
27 Jul · Meeting
Our members' register and share transfer books will remain closed from 16th August, 2007 to 23rd August, 2007 (both days inclusive) for the purpose of Annual General Meeting (which is scheduled to be held on 23rd August, 2007) and for payment of final dividend at the rate of Rs.3.50 per share (35%)18 Jul · Board meeting
Meeting on 26 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”9 Jul · Miscellaneous
Hikal has signed a mutually exclusive long-term agreement with Alpharma Inc., a US based global specialty pharmaceutical company for manufacture and supply of an Active Pharmaceutical Ingredient (API) for the Veterinary sector. Hikal will be manufacturing the API at its USFDA approved plant at Jigani, Bangalore. The total value of the contract is estimated to be Rs.200 crores approx5 Jul · Miscellaneous
Financial results from the Annual Accounts for the year ended March 31, 2007 which were approved by the Board of Directors in their meeting held on July 05, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jul · Dividend
Board has recommended Final Dividend on Equity Share Capital @ 35% (Rs.3.50 per equity Share), in their meeting held on July 05, 2007 for the financial year 2006-07. Company has already declared interim dividend @ Rs.3.00 (Rupees Three) 30% per share which was paid in February 2007. Final dividend is subject to the approval of Shareholders in the Annual General Meeting.3 Jul · Meeting
Minutes of the Extra Ordinary General Meeting of the Shareholders of the Company held on June 14, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
26 Jun · Board meeting
To consider and to take on record the Audited Financial Results and recommendation of final dividend for the year ended March 31, 2007.7 Jun · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended March 31, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
23 May · Redemption
The company has redeemed 4,698,225 Nos. - 7% Cumulative Redeemable Preference Shares of Rs.100/- each aggregating Rs.469,822,500 at par on 23rd May, 2007, in terms of the subscription agreement with the preference shareholders
Apr 2007
17 Apr · Board meeting
To consider and to take on record the Unaudited Financial Results for the quarter ended March 31, 2007.
Feb 2007
6 Feb · Corporate action
Company has fixed the Record Date for the payment of Interim Dividend for the year 2006-07 as February 15, 2007.6 Feb · Dividend
Interim dividend for the year 2006-2007 on the equity shares will be paid on 27th February 2007.
Jan 2007
30 Jan · Dividend
Board at its meeting held on January 30,2007 has declared Interim Dividend @ 30% i.e. Rs. 3/- (Rupees Three only) per share on the Equity Share Capital of the Company for the year 2006-07.22 Jan · Board meeting
To consider and to take on record the Unaudited Financial Results for the quarter ended 31st December, 2006. Further the Company has informed the exchange that the Board will also consider the declaration of Interim Dividend for the Year 2006-2007.